By Kamal Choudhury March 26 (Reuters) - Wave Life Sciences shares plunged 58% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement at reducing a ...

By Siddhi Mahatole March 26 (Reuters) - Shares of Kodiak Sciences surged 68.6% to their highest in more than four years on ...

Wave Life Sciences (WVE) shares crashed more than 50% on Mardh 26 after the company’s interim Phase 1 data for its obesity ...

Kodiak Sciences recently reported positive topline results from its GLOW2 Phase 3 study, where Zenkuda (tarcocimab tedromer) showed superiority to sham in treating a broad range of diabetic ...

For Jonathan Snover, the North Carolina Biotechnology Center's Western Region Executive Director based in Asheville, the ...

Wave Life Sciences (WVE) stock plunges as the company interim data from an early-stage trial for WVE-007, its RNA-based ...

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) is one of the popular penny stocks on Robinhood to buy. On March 17, SELLAS Life ...

Gilead Sciences has experienced a significant valuation re-rating, now trading at 16-17x earnings after doubling from 2024 lows. Read why GILD stock is a hold.

Gilead Sciences plans to acquire Ouro Medicines for up to about $2.18 billion and develop the assets from the deal in a ...

The February release of a report on the future of the Institute of Education Sciences has offered Washington a plan for ...

Wave Life Sciences (NASDAQ:WVE) shares are trading near historic lows after two Wall Street firms cut their price targets ...

Shares of Kodiak Sciences shot higher after the company disclosed what it called positive results from a late-stage study of its treatment for diabetic retinopathy, a progressive disease that occurs ...